Human Subjects Research
Researchers submitting studies involving human participants must meet the following requirements:
- Obtain prior approval for human subjects research by an institutional review board (IRB) or equivalent ethics committee(s)
- Declare compliance with ethical practices upon submission of a manuscript
- Report details on how informed consent for the research was obtained (or explain why consent was not obtained)
- Submit, upon request from the journal, documentation from the review board or ethics committee confirming approval of the research.
- For clinical trials, provide trial registration details, the study protocol, and CONSORT documentation (more information below)
- Confirm that an identified individual has provided written consent for the use of that information
All submissions describing clinical research and/or research on human subjects will be checked by journal staff to ensure that the requirements above are met. Failure to meet requirements may be grounds for rejection. If issues are discovered after publication, we may issue a correction or retraction as appropriate. We also reserve the right to contact the author’s institution.
Clinical investigations must be conducted according to the principles expressed in the Declaration of Helsinki.
PLOS follows the World Health Organization’s (WHO) definition of a clinical trial:
Our policies for clinical trial submissions are designed to promote transparency and reproducibility and to ensure the integrity of the reporting of patient-centered trials. Compliance with our policies is required at submission in order for a manuscript to proceed.
Editors and reviewers should carefully review trial protocols and registration details and assess manuscripts according to CONSORT or other relevant guidelines. Most clinical trial submissions will also be reviewed by a statistician.
Concerns about clinical trial submissions should be brought to the attention of the editorial office as quickly as possible.
Registering clinical trials
All trials submitted to PLOS must be entered in a publicly accessible registry approved by the WHO or ICMJE. See the list of approved registries.
PLOS journals consider prospective trial registration (that is, registration before participant enrollment has begun) to be best publication practice, as recommended by the ICMJE. Clinical trials that began to enroll participants before ICMJE recommendations took effect on July 1, 2005 may be retrospectively registered.
Authors wishing to submit a clinical trial that was not publicly registered before participant enrollment began must register the trial retrospectively in a publicly accessible registry. They must also:
- Register all related clinical trials and confirm they have done so in the Methods section
- Explain in the Methods the specific reasons for failing to register before participant enrollment
- Confirm that future trials will be registered prospectively
PLOS journal editors may decline to further consider any clinical trial for which, in the editor’s judgment, absence of prospective registration raises concerns of selective publication or selective reporting of research outcomes.
PLOS supports the public disclosure of all clinical trial results, as mandated, for example, by the 2007 FDA Amendments Act. Prior disclosure of results on a clinical trial registry site will not affect consideration.
Clinical trial reports must adhere to the relevant reporting guidelines for their study design, such as CONSORT for randomized controlled trials, TREND for non-randomized trials, and other specialized guidelines as appropriate.
For all clinical trial submissions, authors must include the following:
- Registration details (reported in the Methods section and in the submission form)
- CONSORT checklist or relevant reporting guideline (uploaded as supporting information)
- CONSORT flow diagram (uploaded as Fig 1)
- Trial protocol (uploaded as supporting information)
- Details of prior approval for human subjects research by an institutional review board (IRB) or equivalent ethics committee(s)
The submission will not be considered if documentation is not provided. The checklist, flow diagram, and protocol will be published with the article if the manuscript is accepted.
The manuscript file must include the following information:
- An explanation of any deviation from the trial protocol
- Description of informed consent obtained from participants
- Any information on statistical methods or participants not indicated in the CONSORT documentation
PLOS reserves the right to ask for a blank sample copy of any forms used in the trial.
We uphold the right to anonymity and take all necessary steps to protect the privacy of those who participate in research.
Authors must avoid providing identifying information unless strictly necessary for the submission. If identifying information is necessary, authors must confirm that the individual has provided written consent for the use of that information as per the Consent Form for Publication in a PLOS Journal.
All submissions are checked for documentation of patient consent for publication and for any potentially identifying information. Submissions that include identifying patient information without appropriate patient consent will not be considered for publication.
If identifying information is discovered after publication, the article will be temporarily withdrawn while any content compromising participant privacy is removed.
At submission, authors must declare what cell lines were used. Describing sources of cell lines indicates their origin and allows for the research to be reproduced.
For de novo cell lines derived from human tissue, authors must confirm that they obtained approval from an institutional review board or equivalent ethics committee and consent from the donor or next of kin.
Manuscripts using cell lines are checked at initial submission. Those that do not meet the requirements for cell line research will be rejected. Issues with cell lines’ identity, ethical oversight, or potential contamination discovered after publication may lead to a correction or retraction.
Editors and reviewers should evaluate cell line information during peer review and notify the journal if any concerns arise.